A chalcone derivative SBD-2 exerts anticancer effects in human colorectal cancer cells

IF 3.4 Q2 PHARMACOLOGY & PHARMACY

Future Journal of Pharmaceutical Sciences Pub Date : 2024-08-06 DOI:10.1186/s43094-024-00672-8

Bowen Zheng, Wanjun Lin, Na Zhang, Xiaoming Huang, Jingjing Du, Yunfu Shen, Junhe Chen, Qianyu Lin, Zhuya Yang, Wenzhe Ma

引用次数: 0

Abstract

Background

In this study, the potential anticancer activity and mechanism of action of SBD-2, a chalcone isolated from Shuteria involucrata, was investigated in colorectal cancer (CRC) cells.

Results

SBD-2 inhibited the proliferation of Caco-2 cells in a dose-dependent manner. It elicited the cells arrested in the G2/M phase and induced apoptosis. Mechanistically, SBD-2 inhibited Akt phosphorylation, which suppressed the ani-apoptotic protein Bcl-2 and cell cycle regulator Cyclin B1, leading to apoptosis ad cycle arrest, respectively.

Conclusions

The presented chalcone compound SBD-2 from Shuteria involucrata induced apoptosis and cell cycle arrest through inhibiting Akt pathway, highlighting the possibility to develop as a new agent for CRC treatment.

查看原文本刊更多论文

一种查尔酮衍生物 SBD-2 在人类结直肠癌细胞中发挥抗癌作用

本研究调查了 SBD-2 在结直肠癌（CRC）细胞中的潜在抗癌活性和作用机制，SBD-2 是一种从 Shuteria involucrata 中分离出来的查尔酮。SBD-2 以剂量依赖的方式抑制了 Caco-2 细胞的增殖。它能使细胞停滞在 G2/M 期，并诱导细胞凋亡。从机理上讲，SBD-2 可抑制 Akt 磷酸化，从而抑制细胞凋亡蛋白 Bcl-2 和细胞周期调节因子 Cyclin B1，分别导致细胞凋亡和周期停滞。本研究介绍的梭梭属内卷卷叶查尔酮化合物 SBD-2 通过抑制 Akt 通路诱导细胞凋亡和细胞周期停滞，有望开发成治疗 CRC 的新药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

23 weeks

期刊介绍： Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.